Holen Sie sich die Stockscreener-App
10.31
3.91%
-0.42
Vorhandelsmarkt:
9.81
-0.50
-4.85%
Schlusskurs vom Vortag:
$10.73
Offen:
$12.93
24-Stunden-Volumen:
3.96M
Relative Volume:
28.23
Marktkapitalisierung:
$142.84M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.89M
KGV:
-14.73
EPS:
-0.7
Netto-Cashflow:
$-6.48M
1W Leistung:
+7.28%
1M Leistung:
+23.92%
6M Leistung:
+12.07%
1J Leistung:
-23.69%
1-Tages-Spanne:
$10.11
$14.19
1-Wochen-Bereich:
$9.50
$14.19
52-Wochen-Spanne:
$7.78
$14.47
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Firmenname
Greenwich Lifesciences Inc
Sektor
Branche
Telefon
203-434-3290
Adresse
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Vergleichen Sie GLSI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
10.31 | 148.66M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-20 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-09-01 | Eingeleitet | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Aktie (GLSI) Neueste Nachrichten
Greenwich LifeSciences (GLSI) Stock: Soars on 80% Recurrence Reduction Breast Cancer Vaccine Shows Promise in Phase III Trial - parameter.io
Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine? - Benzinga
Greenwich LifeSciences shares jump on early breast cancer trial readout - MSN
Why Is GLSI Stock Rising Today? - Asianet Newsable
Greenwich LifeSciences stock soars after promising cancer trial results By Investing.com - Investing.com Canada
Greenwich LifeSciences Reports 80% Reduction in Breast Cancer Recurrence in FLAMINGO-01 Clinical Trial's Non-HLA-A*02 Arm - Quiver Quantitative
Greenwich LifeSciences (Nasdaq: GLSI) sees ~80% recurrence cut in 250-patient FLAMINGO-01 arm - Stock Titan
What analysts say about Greenwich LifeSciences Inc stockChart Pattern Recognition & Low Risk Trading Alerts - earlytimes.in
What is Noble Financial’s Estimate for GLSI FY2025 Earnings? - Defense World
What drives Greenwich LifeSciences Inc stock price - earlytimes.in
Aug Retail: Will Greenwich LifeSciences Inc stock outperform growth indexesTreasury Yields & Expert-Curated Trade Recommendations - moha.gov.vn
Noble Financial Issues Pessimistic Outlook for GLSI Earnings - MarketBeat
(GLSI) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Greenwich LifeSciences completes enrollment in Phase III trial arm - Investing.com
Greenwich LifeSciences completes enrollment in Phase III trial arm By Investing.com - Investing.com India
Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01 - The Manila Times
Greenwich LifeSciences (Nasdaq: GLSI) finishes 250-patient arm, targets 88,000 eligible - Stock Titan
How Greenwich LifeSciences Inc. stock reacts to global recession fearsMarket Growth Summary & Real-Time Volume Trigger Notifications - Newser
Greenwich LifeSciences reaches 1,000 patient screening milestone By Investing.com - Investing.com Nigeria
Greenwich Lifesciences provides global update on Flamingo-01 - marketscreener.com
Greenwich LifeSciences reaches 1,000 patient screening milestone - Investing.com
Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date - The Manila Times
Greenwich LifeSciences, Inc. Reports Milestone Achievement in FLAMINGO-01 Clinical Trial with Over 1,000 Patients Screened - Quiver Quantitative
Greenwich LifeSciences (GLSI) Stock Analysis Report | Financials & Insights - Benzinga
Greenwich LifeSciences, Inc. (GLSI) stock price, news, quote and history - Yahoo Finance UK
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases $38,502.00 in Stock - MarketBeat
(GLSI) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Greenwich LifeSciences CEO Patel buys $38k in GLSI stock By Investing.com - Investing.com Canada
Is Greenwich LifeSciences Inc. stock safe for conservative investorsRate Cut & Real-Time Volume Analysis - newser.com
Why Greenwich LifeSciences Inc. stock remains on watchlistsEarnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
Greenwich LifeSciences Inc. stock daily chart insightsQuarterly Growth Report & Technical Pattern Recognition Alerts - newser.com
What recovery options are there for Greenwich LifeSciences Inc.July 2025 Summary & Expert Approved Momentum Trade Ideas - newser.com
(GLSI) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Can Greenwich LifeSciences Inc. stock surprise with earnings upside2025 EndofYear Setup & Expert Verified Movement Alerts - newser.com
Greenwich LifeSciences (NASDAQ:GLSI) Releases Earnings Results, Meets Expectations - MarketBeat
How to interpret RSI for Greenwich LifeSciences Inc. stockMarket Growth Summary & Expert Curated Trade Ideas - newser.com
Key resistance and support levels for Greenwich LifeSciences Inc.Watch List & Community Verified Swing Trade Signals - newser.com
Published on: 2025-11-14 19:58:18 - newser.com
Published on: 2025-11-14 17:28:35 - newser.com
Greenwich LifeSciences, Inc. SEC 10-Q Report - TradingView
Published on: 2025-11-14 13:13:03 - newser.com
When is the best time to exit Greenwich LifeSciences Inc.Trade Exit Summary & AI Based Buy and Sell Signals - newser.com
What candlestick patterns are forming on Greenwich LifeSciences Inc.July 2025 Setups & Verified Swing Trading Watchlists - newser.com
Several Insiders Invested In Greenwich LifeSciences Flagging Positive News - Yahoo Finance
Finanzdaten der Greenwich Lifesciences Inc-Aktie (GLSI)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):